BACKGROUND

The Philippines faces a significant Human immunodeficiency virus (HIV) burden, but only 13% of pulmonary tuberculosis (PTB) patients are aware of their status. Barriers to testing include cost, access, risk perception, and stigma. 

OBJECTIVE

To determine the barriers to HIV counseling and testing among clinically confirmed pulmonary tuberculosis patients seen at Corazon C. Aquino Hospital.

METHOD

Cross-sectional research design was employed in this study. Socio-demographic profile and potential barriers to HIV counseling and testing of the respondents was analyzed through descriptive statistics, association was determined through Chi-square. Total enumeration sampling was employed, 33 clinically diagnosed PTB patients was included in this study. 

RESULTS

Results of the study showed 57.58% of respondents lack knowledge about HIV counseling and testing with M < 3.1212. The perceived personal barriers of the respondents are poor knowledge, not perceiving themselves as at risk, and 48.48% not perceiving a benefit in accepting HIV counseling and testing. Socioeconomic barriers include privacy, cost, and fear of rejection from family and friends. Health institutional barriers include unfriendly service providers, privacy issues, queues, delayed results, remote locations, and unavailability. The demographic profile did not significantly correlate with these barriers. 

CONCLUSION

Increase awareness across all populations is recommended since no correlation with demographic profile was found in this study. Mixed-methods is recommended in this study, to reduce recall bias, validate respondents’ narratives and explore other perceived barriers, increase in sample size is also recommended. 

Human ; Tuberculosis, Pulmonary ; Human Immunodeficiency Virus ; Hiv ; Hiv Testing

Among pregnant women, 1-2% are anti-Ro positive and while half of them have symptoms of connective tissue disease, the rest are asymptomatic. The presence of anti-Ro is of concern because of the risk of congenital heart block in the child. We report the case of an asymptomatic 27-year-old G2P1(1001) woman, who presented with persistent fetal bradycardia in her 21st week of gestation (AOG) and was found to have elevated titers for anti-Ro (>320 U/ml). Hydroxychloroquine 200 mg/day and prednisone 10 mg/day were given from the 33rd week of gestation up until the delivery. At 37 weeks AOG, she delivered a live male neonate with a complete heart block. On the 6th day of life, the infant remained bradycardic, hence a pacemaker was inserted and heart rate maintained at 100-120 bpm. On subsequent follow-ups, the mother and child did not develop any systemic manifestations and the infant was thriving well. While a diseased condition may not be apparent in a pregnant anti-Ro positive woman, the risk of neonatal lupus (NL) is demonstrated in this patient’s case. This report illustrates how prenatal care of an asymptomatic woman led to the discovery of a fetal abnormality and served to prepare the family and the medical team to ably handle the birth and subsequent care of a neonate with NL.